527 related articles for article (PubMed ID: 35596010)
1. M6A regulator expression patterns predict the immune microenvironment and prognosis of non-small cell lung cancer.
Liu X; Ma C; Liu H; Sun Z; Luo J
J Cancer Res Clin Oncol; 2022 Oct; 148(10):2803-2814. PubMed ID: 35596010
[TBL] [Abstract][Full Text] [Related]
2. Integrative Analysis of m6A RNA Methylation Regulators and the Tumor Immune Microenvironment in Non-Small-Cell Lung Cancer.
Zhu J; Jiang Y; Wang T; Wu A; Zhou T; Zhang A; Tang Y; Shen Z; Wang J; Zhou H; Shi J; Chen J
Dis Markers; 2022; 2022():2989200. PubMed ID: 35186164
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
Front Immunol; 2021; 12():669750. PubMed ID: 34054840
[TBL] [Abstract][Full Text] [Related]
4. N6-methyladenosine with immune infiltration and PD-L1 in hepatocellular carcinoma: novel perspective to personalized diagnosis and treatment.
Shi Y; Wang Y; Zhang W; Niu K; Mao X; Feng K; Zhang Y
Front Endocrinol (Lausanne); 2023; 14():1153802. PubMed ID: 37469973
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive characterization of tumor microenvironment and m6A RNA methylation regulators and its effects on PD-L1 and immune infiltrates in cervical cancer.
Ji H; Zhang JA; Liu H; Li K; Wang ZW; Zhu X
Front Immunol; 2022; 13():976107. PubMed ID: 36091006
[TBL] [Abstract][Full Text] [Related]
6. Exploring the role of m6A methylation regulators in glioblastoma multiforme and their impact on the tumor immune microenvironment.
Deng X; Sun X; Hu Z; Wu Y; Zhou C; Sun J; Gao X; Huang Y
FASEB J; 2023 Sep; 37(9):e23155. PubMed ID: 37606566
[TBL] [Abstract][Full Text] [Related]
7. Hsa-LINC02418/mmu-4930573I07Rik regulated by METTL3 dictates anti-PD-L1 immunotherapeutic efficacy via enhancement of Trim21-mediated PD-L1 ubiquitination.
Sun Z; Mai H; Xue C; Fan Z; Li J; Chen H; Huo N; Kang X; Tang C; Fang L; Zhao H; Han Y; Sun C; Peng H; Du Y; Yang J; Du N; Xu X
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38040417
[TBL] [Abstract][Full Text] [Related]
8. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
[No Abstract] [Full Text] [Related]
9. HNRNPC, a predictor of prognosis and immunotherapy response based on bioinformatics analysis, is related to proliferation and invasion of NSCLC cells.
Gu Z; Yang Y; Ma Q; Wang H; Zhao S; Qi Y; Li Y
Respir Res; 2022 Dec; 23(1):362. PubMed ID: 36536402
[TBL] [Abstract][Full Text] [Related]
10. Exploring the prognostic potential of m6A methylation regulators in low-grade glioma: implications for tumor microenvironment modulation.
Wu H; Chen S; Hu Z; Ge R; Ma L; You C; Huang Y
Eur J Med Res; 2024 Jan; 29(1):19. PubMed ID: 38173044
[TBL] [Abstract][Full Text] [Related]
11. The significance of m6A RNA methylation modification in prognosis and tumor microenvironment immune infiltration of cervical cancer.
Guo Y; Bai Y; Wang L; Xu Z; Wang X; Wang W
Medicine (Baltimore); 2022 Jul; 101(26):e29818. PubMed ID: 35777046
[TBL] [Abstract][Full Text] [Related]
12. Quantification of m6A RNA methylation modulators pattern was a potential biomarker for prognosis and associated with tumor immune microenvironment of pancreatic adenocarcinoma.
Wang L; Zhang S; Li H; Xu Y; Wu Q; Shen J; Li T; Xu Y
BMC Cancer; 2021 Jul; 21(1):876. PubMed ID: 34332578
[TBL] [Abstract][Full Text] [Related]
13. [CD45RO⁺ Memory T Lymphocytes As A Candidate Marker for Non-small Cell Lung Cancer].
Tan Q; Li H; Yu M; Tang X; Tan J; Zhang S; Wang J
Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):254-264. PubMed ID: 33910273
[TBL] [Abstract][Full Text] [Related]
14. Four m6A RNA Methylation Gene Signatures and Their Prognostic Values in Lung Adenocarcinoma.
Wang Y; Zhao X; Li J; Wang X; Hu W; Zhang X
Technol Cancer Res Treat; 2022; 21():15330338221085373. PubMed ID: 35343834
[No Abstract] [Full Text] [Related]
15. Comprehensive characterization of m6A methylation and its impact on prognosis, genome instability, and tumor microenvironment in hepatocellular carcinoma.
Yin T; Zhao L; Yao S
BMC Med Genomics; 2022 Mar; 15(1):53. PubMed ID: 35260168
[TBL] [Abstract][Full Text] [Related]
16. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
17. Correlation of m6A methylation with immune infiltrates and poor prognosis in non-small cell lung cancer via a comprehensive analysis of RNA expression profiles.
Dong B; Wu C; Li SH; Huang L; Zhang C; Wu B; Sheng Y; Liu Y; Ye G; Qi Y
Ann Transl Med; 2021 Sep; 9(18):1465. PubMed ID: 34734017
[TBL] [Abstract][Full Text] [Related]
18. A Novel m6A-Related LncRNA Signature for Predicting Prognosis, Chemotherapy and Immunotherapy Response in Patients with Lung Adenocarcinoma.
Shen Y; Wang S; Wu Y
Cells; 2022 Aug; 11(15):. PubMed ID: 35954243
[TBL] [Abstract][Full Text] [Related]
19. Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment.
Zhou H; Zheng M; Shi M; Wang J; Huang Z; Zhang H; Zhou Y; Shi J
BMC Cancer; 2021 Aug; 21(1):938. PubMed ID: 34416861
[TBL] [Abstract][Full Text] [Related]
20. m6A Regulator-Mediated Methylation Modification Patterns and Tumor Microenvironment Infiltration Characterization in Acute Myeloid Leukemia.
Du A; Wu X; Gao Y; Jiang B; Wang J; Zhang P; Zhao Q
Front Immunol; 2021; 12():789914. PubMed ID: 34887874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
